Image credit: shutterstock
Heidelberg Pharma AG and Japan-based Chiome Bioscience have announced the signing of an exclusive, target-specific research and option agreement. Heidelberg Pharma Research GmbH signed this collaboration, which will combine one of Chiome’s monoclonal antibodies against one specific target with Heidelberg Pharma’s proprietary ATACplatform.
Under the terms of the agreement, Chiome will have access to Heidelberg Pharma’s Amanitin toxin-linker platform technology and has an option for an exclusive, target-specific license for global development and commercialization rights to the product candidate resulting from the research collaboration.
Heidelberg Pharma would be eligible to receive an option fee, development- and sales-related milestone payments of up to 105 million Euro as well as tiered royalties in the mid-upper single digit range.
